Novartis (NVS)

[DewDiligence]

PDUFA date for NVS’ BAF312 in SPMS—>Mar 2019 (with priority review voucher):

https://globenewswire.com/news-release/2018/10/08/1617727/0/en/Novartis-announces-FDA-and-EMA-filing-acceptance-of-siponimod-the-first-and-only-drug-shown-to-meaningfully-delay-disability-progression-in-typical-SPMS-patients.html

In the EU, an MAA has been submitted, and regulatory action is expected in late 2019.